Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe clinical trial record for pembrolizumab and epacadostat in thymic carcinoma is now displayed, with details on the study design, eligibility, treatments, outcomes, collaborators, and location. It also includes study history, publications, and a study protocol document.SummaryDifference50%

- Check19 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1; the displayed page remains a 403 error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study page now renders a 403 Forbidden error screen instead of the expected content, signaling blocked access to the study record with a basic header and a Home option.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.